v3.25.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2025
Fair Value Measurements  
Schedule of carrying amounts and estimated fair values of the financial instruments

Additional information regarding the methods and assumptions used to estimate the fair value of the financial statements can be found in our Annual Report. The following tables show the carrying amounts and estimated fair values of the Company’s financial instruments (dollars in thousands):

Fair Value Measurements at June 30, 2025 using

    

Carrying
Value

    

Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)

    

Significant
Other
Observable
Inputs
(Level 2)

    

Significant
Unobservable
Inputs
(Level 3)

    

Fair Value

FINANCIAL ASSETS:

Cash and restricted cash

$

11,677

$

11,677

$

$

$

11,677

Loans, net

91,063

88,673

88,673

Investment in joint venture

873

873

873

Other investments

1,096

1,096

1,096

Accrued interest receivable

424

424

424

Servicing assets

179

179

179

FINANCIAL LIABILITIES:

Other secured borrowings

6

6

6

Debt certificates payable

94,620

94,116

94,116

Other financial liabilities

123

123

123

Fair Value Measurements at December 31, 2024 using

    

Carrying
Value

    

Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)

    

Significant
Other
Observable
Inputs
(Level 2)

    

Significant
Unobservable
Inputs
(Level 3)

    

Fair Value

FINANCIAL ASSETS:

Cash and restricted cash

$

10,771

$

10,771

$

$

$

10,771

Certificates of deposit

1,304

1,308

1,308

Loans, net

93,171

90,684

90,684

Investments in joint venture

873

873

873

Other investments

1,082

1,082

1,082

Accrued interest receivable

447

447

447

Servicing assets

177

177

177

FINANCIAL LIABILITIES:

Other secured borrowings

6

$

$

$

6

$

6

Debt certificates payable

95,073

94,031

94,031

Other financial liabilities

479

479

479

Schedule of fair value of assets measured on a nonrecurring basis

The following table presents the fair value of assets measured on a nonrecurring basis (dollars in thousands):

Fair Value Measurements Using:

    

Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)

    

Significant
Other
Observable
Inputs
(Level 2)

    

Significant
Unobservable
Inputs
(Level 3)

    

Total

Assets at June 30, 2025:

Collateral-dependent impaired loans (net of allowance and discount)

$

$

$

7,236

$

7,236

Discounted cash flow loans (net of allowance and discount)

7,105

7,105

Investment in joint venture

873

873

Other investments

1,096

1,096

Foreclosed assets (net of allowance)

301

301

Total

$

$

$

16,611

$

16,611

Assets at December 31, 2024:

Collateral-dependent impaired loans (net of allowance and discount)

$

$

$

9,535

$

9,535

Discounted cash flow loans (net of allowance and discount)

7,133

7,133

Investments in joint venture

873

873

Other investments

1,082

1,082

Foreclosed assets (net of allowance)

301

301

Total

$

$

$

18,924

$

18,924

Summary of valuation methodologies used to measure the fair value adjustments for Level 3 assets recorded at fair value on a nonrecurring basis

The table below summarizes the valuation methodologies used to measure the fair value adjustments for Level 3 assets recorded at fair value on a nonrecurring basis (dollars in thousands):

June 30, 2025

Assets

    

Fair Value
(in thousands)

    

Valuation
Techniques

    

Unobservable
Input

    

Range
(Weighted Average)

Collateral dependent loans

$

7,236

Discounted appraised value

Selling cost / Estimated market decrease

10% (10%)

Other impaired loans

7,105

Discounted future cash flows

Discount rate

4% (4%)

Investment in joint venture

873

Internal evaluations

Estimated future market value

0% (0%)

Other investments

1,096

Internal evaluations

Indications of non-performance by insurance companies

0% (0%)

Foreclosed Assets

301

Internal evaluations

Selling cost

6% (6%)

December 31, 2024

Assets

    

Fair Value
(in thousands)

    

Valuation
Techniques

    

Unobservable
Input

    

Range
(Weighted Average)

Impaired loans

$

9,535

Discounted appraised value

Selling cost / Estimated market decrease

10% (10%)

Other impaired loans

7,133

Discounted future cash flows

Discount rate

4% (4%)

Investments in joint venture

873

Internal evaluations

Estimated future market value

0% (0%)

Other investments

1,082

Internal evaluations

Indications of non-performance by insurance companies

0% (0%)

Foreclosed assets

301

Internal evaluations

Selling cost

6% (6%)